The SWISH trial, a Phase II clinical trial [64] confirms that in a postmenopausal patient with HR‐positive/HER2‐negative advanced breast cancer receiving everolimus plus endocrine therapy, preventive use of glucocorticoid‐containing mouthwash could decrease the risk of stomatitis. The gene discussed is ERBB2; the disease is breast cancer.